Identification
NameIcodextrin
Accession NumberDB00702  (APRD01026)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.

Structure
Thumb
Synonyms
Icodextrin
Icodextrina
Icodextrine
Icodextrinum
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdeptBaxter
Dextrin, CaloreenBaxter
IcodialNot Available
Brand mixtures
NameLabellerIngredients
ExtranealBaxter Laboratories
Categories
UNII2NX48Z0A9G
CAS number337376-15-5
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
Indication

Used for continuous ambulatory peritoneal dialysis (CAPD) of diabetic patients or automated peritoneal dialysis (APD) for the management of end-stage renal disease.

Structured Indications Not Available
Pharmacodynamics

Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.

Mechanism of action

Icodextrin is a starch-derived, water-soluble glucose polymer linked by alpha (1-4) and alpha (1-6) glycosidic bonds with an average molecular weight between 13,000 and 19,000 daltons. It functions as a colloid osmotic agent to achieve ultrafiltration during long (12-16 hour) peritoneal dialysis dwells. In other words it helps clean waste out of the body when the kidneys are not functioning properly. Icodectrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration through the dwell. This is due to the fact that the polymer is minimially absorbed across the peritoneal membrane. Icodextrin achieves superior fluid removal compared with glucose-based dialysates.

Related Articles
Absorption

40% of instilled icodextrin was absorbed from the peritoneal solution during a 12-hour dwell.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Icodextrin is metabolized by alpha-amylase into oligosaccharides with a lower degree of polymerization), including maltose, maltotriose, maltotetraose, and higher molecular weight species.

SubstrateEnzymesProduct
Icodextrin
Not Available
MaltoseDetails
Icodextrin
Not Available
MaltotrioseDetails
Icodextrin
Not Available
MaltotetraoseDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions No interactions found.
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Frampton JE, Plosker GL: Icodextrin: a review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079-105. [PubMed:12962523 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (243 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentCongestive Heart Failure (CHF)1
2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD)1
3CompletedTreatmentContinuous ambulatory peritoneal dialysis therapy / Diabetes / End Stage Renal Disease (ESRD)1
3CompletedTreatmentDiabetes / ESRD1
3Unknown StatusTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentAPD / Continuous ambulatory peritoneal dialysis therapy / Diabetes / ESRD1
4CompletedTreatmentChronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
4CompletedTreatmentPeritonitis1
4RecruitingTreatmentImpaired Renal Function1
Not AvailableActive Not RecruitingPreventionSurgical Adhesions1
Not AvailableCompletedPreventionLaparoscopic Hysterectomy1
Not AvailableRecruitingTreatmentEnd Stage Renal Disease (ESRD)1
Not AvailableTerminatedTreatmentPeritoneal dialysis therapy1
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntraperitoneal
SolutionIntraperitoneal
Prices
Unit descriptionCostUnit
Extraneal icodextrin dial soln0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4761237 No1992-08-092009-08-09Us
US6077836 No1997-06-202017-06-20Us
US6248726 No1998-06-192018-06-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility80 mg/mLNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Chloride ion binding
Specific Function:
Not Available
Gene Name:
AMY2A
Uniprot ID:
P04746
Molecular Weight:
57706.51 Da
References
  1. Flore KM, Delanghe JR: Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int. 2009 Jul-Aug;29(4):377-83. [PubMed:19602602 ]
  2. Garcia-Lopez E, Lindholm B: Icodextrin metabolites in peritoneal dialysis. Perit Dial Int. 2009 Jul-Aug;29(4):370-6. [PubMed:19602601 ]
Drug created on June 13, 2005 07:24 / Updated on July 22, 2017 12:04